Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Effects of a Combination Oral Spray (Mucosamin®) for the Prevention of Oral Mucositis in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Double Blind Randomized Clinical Trial Publisher Pubmed



Shahrabi M1 ; Solduzian M2 ; Babaie MH1, 3 ; Mousavi SA4 ; Goodarzi N5 ; Ravari NS6 ; Sadeghi K1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, 16-Azar St., Enghelab Ave, Tehran, 14176-14418, Iran
  2. 2. Department of Clinical Pharmacy, School of Pharmacy, Tabriz University of Medical Science, Tabriz, Iran
  3. 3. Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Hematology, Oncology, and Hematopoietic Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Nanotechnology Research Centre, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Department of Pharmaceutics, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Source: Supportive Care in Cancer Published:2022


Abstract

Purpose: Oral mucositis (OM) is a frequent complication of conditioning regimens for hematopoietic stem cell transplantation (HSCT). Damage to the nuclear and non-nuclear materials of the mucosal cells by the production of Reactive Oxygen Species (ROS) and proinflammatory cytokines could result to development and progression of OM. Previous studies have shown the effectiveness of Mucosamin® oral spray in the management of pain and acceleration of OM healing. The aims of the current study were to evaluate prophylactic effects of Mucosamin® oral spray in reducing the incidence and severity of OM in pediatric patients undergoing allogeneic HSCT. Method: The current study was designed as a double-blind, placebo-controlled randomized clinical trial. Sixty patients were enrolled in the study and received placebo or Mucosamin® spray. Patients in both groups used sprays 4 times daily. Product application was begun at the time of initiation of conditioning regimen and was continued for 14 days. Results: Mucosamin® significantly reduced incidence and severity of OM compared to the placebo (P values: 0.027 and 0.035, respectively). This product could also decrease OM duration and delay OM onset (P values: 0.007 and 0.006, respectively). Conclusion: Mucosamin® could effectively reduce incidence, severity, and duration of OM and delay OM onset in pediatric patients undergoing allogeneic HSCT. Trial registration: The study protocol was registered in the Iranian Registry of Clinical Trials under the registry number IRCT20190917044805N1. © 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.